Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patterns of Aortic Valve Replacement in Europe: Adoption by Age

T. Rudolph, C. Appleby, V. Delgado, H. Eltchaninoff, C. Gebhard, C. Hengstenberg, W. Wojakowski, N. Petersen, J. Kurucova, P. Bramlage, S. Bleiziffer

. 2023 ; 148 (6) : 547-555. [pub] 20230816

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001314

INTRODUCTION: The management of patients with severe aortic stenosis may differ according to patients' age. The aim of this analysis was to describe patterns of aortic valve replacement (AVR) use in European countries stratified by age. METHODS: Procedure volume data for AVR, including surgical aortic valve replacement (sAVR) and transcatheter aortic valve implantation (TAVI), for the years 2015-2020 were obtained from national databases for twelve European countries (Austria, the Czech Republic, Denmark, England, Finland, France, Germany, Norway, Poland, Spain, Sweden, and Switzerland). Procedure volumes were reported by patient age (<50 years, 5-year age groups between 50 and 85 years, and ≥85 years). Patients per million (PPM) population undergoing AVR each year were calculated using population estimates from Eurostat. RESULTS: AVR PPM varied widely between countries, from 508 PPM in Germany to 174 PPM in Poland in 2020. TAVI rates ranged from 61% in Switzerland and Finland to 25% in Poland. AVR PPM increased with age to a peak at 80-84 years, after which it decreased again. AVR procedures increased from 2015 to 2019 at an average annual rate of 3.9%. AVR increased more substantially in people aged ≥80 years than in younger age groups; these older age groups accounted for 30% of all AVR procedures in 2015 and 35% in 2019. TAVI accounted for an increasing proportion of all AVR procedures as patient age increased; an overall average of 96% of males and 98% of females aged ≥85 years received TAVI as the treatment modality, although adoption of TAVI differed between countries. CONCLUSIONS: There is considerable variation in the rates of AVR use and the adoption of TAVI versus sAVR between European countries. The use of TAVI has increased in recent years, particularly for older patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001314
003      
CZ-PrNML
005      
20240213094536.0
007      
ta
008      
240109s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000533633 $2 doi
035    __
$a (PubMed)37586346
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rudolph, Tanja $u General and Interventional Cardiology/Angiology, Heart and Diabetes Centre Nord Rhine-Westphalia, University Hospital of the Ruhr University Bochum, Bad Oeynhausen, Germany
245    10
$a Patterns of Aortic Valve Replacement in Europe: Adoption by Age / $c T. Rudolph, C. Appleby, V. Delgado, H. Eltchaninoff, C. Gebhard, C. Hengstenberg, W. Wojakowski, N. Petersen, J. Kurucova, P. Bramlage, S. Bleiziffer
520    9_
$a INTRODUCTION: The management of patients with severe aortic stenosis may differ according to patients' age. The aim of this analysis was to describe patterns of aortic valve replacement (AVR) use in European countries stratified by age. METHODS: Procedure volume data for AVR, including surgical aortic valve replacement (sAVR) and transcatheter aortic valve implantation (TAVI), for the years 2015-2020 were obtained from national databases for twelve European countries (Austria, the Czech Republic, Denmark, England, Finland, France, Germany, Norway, Poland, Spain, Sweden, and Switzerland). Procedure volumes were reported by patient age (&lt;50 years, 5-year age groups between 50 and 85 years, and ≥85 years). Patients per million (PPM) population undergoing AVR each year were calculated using population estimates from Eurostat. RESULTS: AVR PPM varied widely between countries, from 508 PPM in Germany to 174 PPM in Poland in 2020. TAVI rates ranged from 61% in Switzerland and Finland to 25% in Poland. AVR PPM increased with age to a peak at 80-84 years, after which it decreased again. AVR procedures increased from 2015 to 2019 at an average annual rate of 3.9%. AVR increased more substantially in people aged ≥80 years than in younger age groups; these older age groups accounted for 30% of all AVR procedures in 2015 and 35% in 2019. TAVI accounted for an increasing proportion of all AVR procedures as patient age increased; an overall average of 96% of males and 98% of females aged ≥85 years received TAVI as the treatment modality, although adoption of TAVI differed between countries. CONCLUSIONS: There is considerable variation in the rates of AVR use and the adoption of TAVI versus sAVR between European countries. The use of TAVI has increased in recent years, particularly for older patients.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a aortální chlopeň $x chirurgie $7 D001021
650    12
$a aortální stenóza $x chirurgie $7 D001024
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
650    12
$a transkatetrální implantace aortální chlopně $x metody $7 D065467
650    12
$a chirurgická náhrada chlopně $x metody $7 D019918
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Appleby, Clare $u Cardiology, Liverpool Heart and Chest Hospital, Liverpool, UK
700    1_
$a Delgado, Victoria $u Heart Institute, Department of Cardiology, Hospital University Germans Trias I Pujol Barcelona, Badalona, Spain
700    1_
$a Eltchaninoff, Helene $u Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, Rouen, France
700    1_
$a Gebhard, Catherine $u Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
700    1_
$a Hengstenberg, Christian $u Division of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria
700    1_
$a Wojakowski, Wojtek $u Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Katowice, Katowice, Poland
700    1_
$a Petersen, Nathan $u Edwards Lifesciences, Nyon, Switzerland
700    1_
$a Kurucova, Jana $u Medical Affairs, Edwards Lifesciences, Prague, Czechia
700    1_
$a Bramlage, Peter $u Institute for Pharmacology und Preventive Medicine, Cloppenburg, Germany, submission@ippmed.de
700    1_
$a Bleiziffer, Sabine $u Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, University Hospital, Ruhr-University Bochum, Bad Oeynhausen, Germany
773    0_
$w MED00001053 $t Cardiology $x 1421-9751 $g Roč. 148, č. 6 (2023), s. 547-555
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37586346 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094533 $b ABA008
999    __
$a ok $b bmc $g 2049755 $s 1211008
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 148 $c 6 $d 547-555 $e 20230816 $i 1421-9751 $m Cardiology $n Cardiology $x MED00001053
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace